36 results
6-K
EX-99.2
MOR
Morphosys AG
30 Oct 19
Third Quarter Interim Statement
10:03am
/lenalidomide combination compared to lenalidomide alone
Rolling submission for BLA initiated: preclinical data package submitted to FDA
MOR202: First clinical … of this year. Rolling submission was initiated and thepre-clinical data package was already submitted to the FDA.
Our commitment to unlock
6-K
EX-99.1
MOR
Morphosys AG
7 May 18
Current report (foreign)
10:21am
to undertake a rolling submission to the FDA, with the last part of the package being available late next year, which means an approval, assuming … a satisfactory data package of course, could be expected in the first half of 2020.
We are planning to start commercialization in the U.S. according
SC14D9C
EX-99.1
MOR
Morphosys AG
15 Mar 24
Written communication relating to third party tender offer
4:46pm
and Europe by the middle of 2024. We are on track with this process and are confident that our comprehensive pelabresib data package will provide impactful … that many companies typically do following positive phase 3 data, and I can just reiterate that we remain confident that the comprehensive data package
6-K
EX-99.1
MOR
Morphosys AG
8 Aug 19
MorphoSys Announces Intention to Submit Marketing Authorization
6:27am
. These data will form the basis for the planned filing package of the MAA that, if granted, allows for earliest approval in Europe in 2021.
“We
SC14D9C
EX-99.1
MOR
Morphosys AG
14 Mar 24
Written communication relating to third party tender offer
4:52pm
priority. We are grateful to the team preparing our comprehensive pelabresib submission package, one that we are confident will provide impactful evidence
SC14D9C
EX-99.4
64o7rke2tavjwhxw94
13 Mar 24
Written communication relating to third party tender offer
5:22pm
SC14D9C
EX-99.1
auir2uo60v3
6 Feb 24
Written communication relating to third party tender offer
4:58pm
SC14D9C
EX-99.2
52oy lmh5za
14 Mar 24
Written communication relating to third party tender offer
4:52pm
6-K
EX-99.1
pjhf7nai56va97v8
6 Aug 18
Current report (foreign)
10:50am
6-K
EX-99.2
w42f5vb m0
7 May 18
Current report (foreign)
10:21am
6-K
EX-99.1
9vab oz1fm3gap2j
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
6-K
EX-99.1
kyoq5i gqi
12 May 21
MorphoSys and Incyte Announce First Patient Dosed in Phase 3
6:19am
6-K
EX-99.2
ib7ana u7y
9 Aug 19
Current report (foreign)
6:18am
6-K
EX-99.2
htcwqof33
14 Mar 24
Current report (foreign)
8:27am
6-K
EX-99.1
9wa47m0c1r
28 Feb 19
Current report (foreign)
8:59am
6-K
EX-99.2
ljesrh tw
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
SC 14D9
EX-99
cqd38h38zc uvi7
11 Apr 24
Tender offer solicitation
11:57am
20-F
fxwfpe 3cb1sfv
13 Mar 19
Annual report (foreign)
5:13pm
6-K
EX-99.1
165vfmg u3j9c5opm
20 Mar 20
Current report (foreign)
2:15pm